

# Sustaining a System of Care




Dr. Edward Zajac  
Cardiovascular Associates, P.C.

UnityPoint Health, St Luke's

May 3<sup>rd</sup>, 2017

# System of Care



\* Golden Hour = First 60 minutes


# Levels of Evidence

**Class I**  
Treatment  
Should Be  
Performed

**Class IIa**  
It is reasonable  
to perform  
procedure or  
administer  
treatment

**Class IIb**  
Procedure or  
Treatment may  
be considered

**Class III**  
Procedure or  
Treatment  
should not be  
performed. Not  
helpful, may be  
harmful.

		SIZE OF TREATMENT EFFECT 			
		CLASS I	CLASS IIa	CLASS IIb	CLASS III
		<i>Benefit &gt;&gt;&gt; Risk</i> Procedure/Treatment <b>SHOULD</b> be performed/administered	<i>Benefit &gt;&gt; Risk</i> Additional studies with focused objectives needed <b>IT IS REASONABLE</b> to perform procedure/ administer treatment	<i>Benefit ≥ Risk</i> Additional studies with broad objectives needed; additional registry data would be helpful Procedure/Treatment <b>MAY BE</b> CONSIDERED	<i>Risk ≥ Benefit</i> Procedure/Treatment should <b>NOT</b> be performed/administered <b>SINCE IT IS NOT</b> <b>HELPFUL AND MAY</b> <b>BE HARMFUL</b>
ESTIMATE OF CERTAINTY (PRECISION) OF TREATMENT EFFECT	<b>LEVEL A</b> Multiple (3-5) population risk strata evaluated* General consistency of direction and magnitude of effect	<ul style="list-style-type: none"> <li>Recommendation that procedure or treatment is useful/effective</li> <li>Sufficient evidence from multiple randomized trials or meta-analyses</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation in favor of treatment or procedure being useful/effective</li> <li>Some conflicting evidence from multiple randomized trials or meta-analyses</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation's usefulness/efficacy less well established</li> <li>Greater conflicting evidence from multiple randomized trials or meta-analyses</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation that procedure or treatment is not useful/effective and may be harmful</li> <li>Sufficient evidence from multiple randomized trials or meta-analyses</li> </ul>
	<b>LEVEL B</b> Limited populations evaluated* Data derived from a single randomized trial or nonrandomized studies	<ul style="list-style-type: none"> <li>Recommendation that procedure or treatment is useful/effective</li> <li>Evidence from single randomized trial or nonrandomized studies</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation in favor of treatment or procedure being useful/effective</li> <li>Some conflicting evidence from single randomized trial or nonrandomized studies</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation's usefulness/efficacy less well established</li> <li>Greater conflicting evidence from single randomized trial or nonrandomized studies</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation that procedure or treatment is not useful/effective and may be harmful</li> <li>Evidence from single randomized trial or nonrandomized studies</li> </ul>
	<b>LEVEL C</b> Very limited populations evaluated* Only consensus opinion of experts, case studies, or standard-of-care	<ul style="list-style-type: none"> <li>Recommendation that procedure or treatment is useful/effective</li> <li>Only expert opinion, case studies, or standard-of-care</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation in favor of treatment or procedure being useful/effective</li> <li>Only diverging expert opinion, case studies, or standard-of-care</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation's usefulness/efficacy less well established</li> <li>Only diverging expert opinion, case studies, or standard-of-care</li> </ul>	<ul style="list-style-type: none"> <li>Recommendation that procedure or treatment is not useful/effective and may be harmful</li> <li>Only expert opinion, case studies, or standard-of-care</li> </ul>
Suggested phrases for writing recommendations <sup>1</sup>		should is recommended is indicated is useful/effective/beneficial	is reasonable can be useful/effective/ beneficial is probably recommended or indicated	may/might be considered may/might be reasonable usefulness/effectiveness is unknown/unclear/uncertain or not well established	is not recommended is not indicated should not is not useful/effective/ beneficial may be harmful

# Regional Systems of STEMI Care, Reperfusion Therapy, and Time-to-Treatment Goals



All communities should create and maintain a regional system of STEMI care that includes assessment and continuous quality improvement of EMS and hospital-based activities.

Performance can be facilitated by participating in programs such as Mission: Lifeline and the D2B Alliance.



Performance of a 12-lead ECG by EMS personnel at the site of FMC is recommended in patients with symptoms consistent with STEMI.

# Regional Systems of STEMI Care, Reperfusion Therapy, and Time-to-Treatment Goals

## LEVELS OF EVIDENCE



**Reperfusion therapy** should be administered to all eligible patients with STEMI with symptom onset within the prior 12 hours.



**Primary PCI is the recommended method of reperfusion** when it can be performed in a timely fashion by experienced operators.



**EMS transport directly to a PCI-capable hospital** for primary PCI is the recommended triage strategy for patients with STEMI with an ideal FMC-to-device time system goal of 90 minutes or less.\*



# Regional Systems of STEMI Care, Reperfusion Therapy, and Time-to-Treatment Goals

## LEVELS OF EVIDENCE

I	IIa	IIb	III
<b>B</b>			


**Immediate transfer to a PCI-capable hospital for primary PCI** is the recommended triage strategy for patients with STEMI who initially arrive at or are transported to a non-PCI-capable hospital, with an FMC-to-device time system goal of 120 minutes or less.\*

I	IIa	IIb	III
<b>B</b>			

**In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI at non-PCI-capable hospitals** when the anticipated FMC-to-device time at a PCI-capable hospital exceeds 120 minutes because of unavoidable delays.

# Regional Systems of STEMI Care, Reperfusion Therapy, and Time-to-Treatment Goals

## LEVELS OF EVIDENCE



When **fibrinolytic therapy** is indicated or chosen as the primary reperfusion strategy, it should be **administered within 30 minutes of hospital arrival**.\*



Reperfusion therapy is reasonable for patients with STEMI and symptom onset within the prior 12 to 24 hours who have clinical and/or ECG evidence of ongoing ischemia. **Primary PCI is the preferred strategy in this population.**

\*The proposed time windows are system goals. For any individual patient, every effort should be made to provide reperfusion therapy as rapidly as possible.


# Sioux City Regional STEMI Task Force

- 1) Goal of Identical PCI-H Systems of Care
  - Pre-hospital treatment recommendations
  - STEMI Alerts
  - PCI-Hospital ED & Referral-Hospital ED expedited care
- 2) Outreach
- 3) Automated Chest Compressions Device
- 4) OOHCA Protocol
- 5) Hypothermia Protocol
- 6) Case Reviews



# CASE REVIEW #1

CASE #1:  
Patient called 911 with complaints of Chest Pain



## CASE #1


- EMS (BLS) dispatched for Chest Pain patient
- 000: FMC
- 003: EKG, and call for paramedic assist
- 016: Heli notified of possible transport need
- 019: Paramedic assist arrival
  - EKG and cardiologist notified of STEMI
- 026: Heli dispatch
- 034: Arrival to nonPCI-H
- 048: Medications ✓
- 063: Heli lands at nonPCI-H
- 084: Heli lift-off
- 087: MI Alert at PCI-H
- 112: Heli lands at PCI-H
- 115: Hand-off of care in CCL
- 144: Device

### Notes to Consider

- FMCtoEKG: 3min
- 84min before heading toward PCI-H
  - Expedite the transfer?
- Fibrinolytics?
- To PCI-H door in 115min.
- PCI-H D2B: 29min
- FMCtoDEVICE: 144min

# CASE REVIEW #2

CASE #2:  
Patient called 911 with complaints of Chest Pain





## CASE #2

- EMS (ALS) dispatch for CP patient
- 000: At patient (FMC)
- 006: EKG – anteroseptal ST elevation
- 007: EKG transmitted
  - MI Alert called to PCI-H
- 008: ASA
- 010: SL Nitro
- 011: Plavix
- 012: Lipitor
- 013: Metoprolol
- 016: Zofran and Fentanyl
- 026: Fentanyl
- 031: O2 per NC
- 049: Pt transfer to Air EMS
- 058: Heli departure to PCI-H
- 066: Heparin
- 075: In PCI-H ED
- 089: In Cardiac Cath Lab
- 102: Device

### Notes to Consider

- FMCtoEKG: 6min
- Moving to PCI-H in < 8min
- Expedited Transfer
- Give Heparin earlier if able
- To PCI-H door in 75min
- PCI-H D2B: 27min
- FMCtoDEVICE: 102min

# Questions....

